DHRDanaher Corporation
$230.45+9.6% 1Y
$230.45
$161.9152 weeks$241.54
The financials
Danaher Corporation by the numbers
Danaher Corporation (DHR) reported revenue of $6.55B in Q3 2026 (quarter ended Sep 25, 2026), up 8.3% from the same quarter a year earlier. That came with a gross margin of 59% and net income of $1.24B (19% of revenue). For the full year FY2025, revenue was $24.6B (+2.9% year on year) and net income $3.61B. Its largest segment in Q2 2026 (quarter ended Jun 26, 2026) was Diagnostics at $1.13B, 46% of the disclosed total, ahead of Life Sciences at 31%. The next results filing is expected around Jan 27, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $6.55B | $6.05B | +8.3% |
| Gross profit | $3.84B | $3.52B | +8.9% |
| Operating income | $1.25B | $1.15B | +7.9% |
| Net income | $1.24B | $908M | +36% |
| Diluted EPS | $1.75 | $1.27 | +38% |
| Operating | Revenue | Share |
|---|---|---|
| Diagnostics | $1.13B | 46% |
| Life Sciences | $759M | 31% |
| Biotechnology | $583M | 24% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $2.47B (-0.16%)
Diagnostics grew +6.4% year on yearBiotechnology -4.7% year on year
Segment Latestquarter on quarteryear on year
- Diagnostics$1.13B$1.13Bquarter on quarter -11%year on year +6.4%-11%+6.4%
- Life Sciences$759.0M$759.0Mquarter on quarter +10%year on year -0.39%+10%-0.39%
- Biotechnology$583.0M$583.0Mquarter on quarter +11%year on year -4.7%+11%-4.7%
On our screens:Stocks that buy back more than they dilute
Diagnostics & Research
The closest names by size in the same industry